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EDITORIAL
Pentaerythrityl tetranitrate (PETN): a better
nitrate?
Elaine Rutherford* and Allan D. Struthers
Division of Cardiovascular and Diabetes Medicine, Medical Research Institute, Ninewells Hospital, Dundee SS1 9SY, UK
This Editorial refers to ‘Efficacy of the long acting nitro vaso-
dilator pentaerithrityltetranitrate in patients with chronic
stable angina pectoris receiving antianginal background
therapy with betablockers: a 12-weeks, randomized,
double-blind, placebo controlled trial’, by Mu¨nzel et al.
Today, patients with coronaryartery disease can expect to live longer
and with less symptom burden than their counterparts of 30 years
ago. This is because of better medical therapies and better revascu-
larization strategies. However, the stalwarts of medical anti-anginal
therapy—the b-blockers, calcium channel blockers, and nitrates—
are not without their problems. Nitrates, although effective at reliev-
ing acute anginal pain and well established as a mainstay of chronic
angina therapy, may have particular problems.1,2 One problem with
nitrates is that traditional nitrate use can increase oxidative stress
and so induceendothelial dysfunction.1 In addition to endothelial dys-
function, another major practical problem with nitrate is nitrate tol-
erance.2 Furthermore, a review of 52 693 patients from the Global
Registry of Acute Coronary Evidence shows that longer-term use
of nitrates is associated with fewer ST elevation myocardial infarc-
tions but more non-ST elevation acute coronary syndromes.3 One
hypothesis is that nitrates might pre-condition the heart more
towards ischaemic episodes. Newer medical therapies—or new
applications of existing therapies—are therefore needed to reduce
the symptom burden in chronic stable angina and, if possible, to
improve prognosis. This need is particularly relevant to those who
have run out of revascularization options.
This is the approach taken by Mu¨nzel et al. in the featured paper.4
They take a fresh look at the long-acting organic nitrate pentaerithri-
tyl tetranitrate (PETN), which has been used as an anti-anginal medi-
cation for over half a century (Figure 1).5 In this work, they chose to
investigate the anti-ischaemic effect of PETN for two reasons.
Firstly, as they and others have previously described, it does not
appear to exhibit the same tolerance-inducing properties as other
nitrates.2,6 Secondly, unlike other nitrates, which are reputed to
induce endothelial dysfunction, there is evidence that in animal
models PETN even improves endothelial function.7,8 This has been
antioxidant enzyme haem oxygenase.7 It is probable that the lack of
induction tolerance of tolerance by PETN and its suggested beneficial
effects on endothelial function are interlinked. In mice, when the
haem oxygenase gene was knocked out, both tolerance and progres-
sive endothelial dysfunction were evident after exposure to PETN.8
Disappointingly, however, despite evidence to the contrary in animal
models, when the PENTA study examined the effect of PETN on
endothelial function in patients with coronary artery disease, no im-
provement in endothelial function was demonstrated, although posi-
tive changes in the microcirculation were seen.9
It may not be coincidence that other therapies thought to have
positive effects on endothelial function have also been demonstrated
to have anti-anginal or anti-ischaemic properties.10212 In other
words, the idea that improving endothelial function and reducing oxi-
dative stress can reduce ischaemia in chronic stable angina is not new.
Testosterone12 and allopurinol11 are two drugs to do this. Both have
been demonstrated to improve endothelial function and have shown
encouraging results in the treatment of the pain of angina.10212 The
role of testosterone as an anti-anginal therapy is impractical,
however, in view of its significant side-effect profile. In contrast, allo-
purinol is well established as a safe drug that is cheap, well tolerated
and has few side-effects. The anti-anginal efficacy of allopurinol
awaits further evaluation in larger-scale and longer-term clinical trials.
In the multinational study by Mu¨nzel et al.,4 the authors sought to
investigate the anti-ischaemic efficacyof PETN 80 mg twice dailyover
placebo in patients with chronic stable angina who were already on
standardanti-anginal therapy includingab-blockerand/or ivabradine.
The primaryoutcomewastotal exercisedurationat12weeks.Aftera
wash-out period from any other long-acting nitrates, patients under-
went treadmill testing at randomization, 6 and 12 weeks. Ultimately,
in the unselected patient group PETN fared no better than placebo.
This is both disappointing and surprising, because a systematic review
and meta-analysis of randomized clinical trials considering nitrate
therapy in stable angina found that both intermittent and continuous
regimensofnitrates lengthenedexercisedurationsignificantlyby31and
53 s, respectively.13 However, PETN, which is a pentaerithrityl nitrate,
was not included in the review search terms; it had already been
removed from the pharmacopoeia in North America and Europe by
the early 1990s because of a lack of data supporting its efficacy.
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Mu¨nzel’s featured study did, however, have some significant posi-
tive findings in a subgroup analysis of those participants who were
most symptomatic with their angina.4 In 120 patients who reported
two episodes or more of angina per week, who took at least two
doses of short-acting nitrates per week, and who exercised for less
than 9 min atbaseline, the change in total exercise duration was mark-
edly larger in the PETN group when compared with placebo. In fact,
the changes in total exercise duration were quite dramatic, with the
change from baseline reaching as much as 48 s in favour of the PETN
group; this is comparable with the data from the systematic review of
traditional nitrate therapy.13 It is perhaps to be expected that the ef-
ficacy of PETN would be greater in those with the worst symptoms.
Ranolazine, which is a relatively new second-line anti-anginal, has
also been studied in severe angina. The CARISA study14 included
patients with known stable angina who were on conventional anti-
anginal therapy with standard doses of atenolol, amlodipine, or diltia-
zem. The study eligibility criteria included a limited total exercise cap-
acity on treadmill testing (3–9 min of a modified Bruce protocol).
Patients were randomized to receive either placebo or two differing
doses of ranolazine. Total exercise duration was again a primary
outcome measure. Ranolazine therapy only extended trough exer-
cise duration by close to 24 s.14 However, in a subsequent post hoc
analysis of 258 patients from the CARISA trial who were considered
to be on maximally tolerated doses ofb-blockers or calcium-channel
blockers (determined by assessment of blood pressure and heart
rate), ranolazine extended the change in baseline exercise duration
to 34.5 s.15 Ivabradine, another accepted second-line anti-anginal in
Europe, also achieved fairly modest improvements in total exercise
time (16.6 s longer than placebo) when compared with the results
of PETN.16 The increase in exercise duration in the subgroup analysis
of the PETN data is comparable with a similar, albeit smaller, study of
allopurinol in unselected angina patients. In that study, the absolute
improvement in exercise duration over placebo was 58 s.11 We
must consider all of these relatively modest improvements in exer-
cise duration before we discount the potential efficacy of PETN.
However, before we can definitively establish whether PETN can
really hold its own amongst other anti-anginal drugs, direct compara-
tive studies are required.
Given the acceptable safety profile and demonstrated clinical ben-
efits of PETN in a carefully selected patient population, as well as its
reported lack of some traditional nitrate therapy drawbacks, there is
likely to be a place for its use amongst other emerging anti-anginal
therapies. However, further evidence of its merit is still required.
The natural next question for PETN proponents is surely whether
PETN therapy could modify longer-term outcomes in the ischaemic
heart disease population. Indeed, this is the testwe need now to apply
to all our new anti-ischaemic treatments in chronic stable angina.
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